uniQure NV (QURE) Shares Down 0.8%
uniQure NV (NASDAQ:QURE) shares were down 0.8% on Monday . The stock traded as low as $8.23 and last traded at $8.42, with a volume of 93,200 shares. The stock had previously closed at $8.49.
QURE has been the topic of several recent research reports. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of uniQure NV in a report on Thursday, June 30th. Leerink Swann reaffirmed a “positive” rating and issued a $27.00 price target on shares of uniQure NV in a report on Tuesday, August 2nd. Chardan Capital set a $35.00 price target on shares of uniQure NV and gave the company a “buy” rating in a report on Thursday, July 28th. HC Wainwright initiated coverage on shares of uniQure NV in a report on Thursday, August 4th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of uniQure NV from a “hold” rating to a “sell” rating in a report on Thursday, August 4th. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.10.
The firm has a 50-day moving average price of $7.95 and a 200-day moving average price of $11.13. The company’s market cap is $209.63 million.
uniQure NV (NASDAQ:QURE) last released its earnings results on Thursday, August 25th. The company reported ($0.87) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.02. On average, analysts expect that uniQure NV will post ($3.48) EPS for the current year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.